Skip to content

OxSonics CEO, Jérôme Marzinski, gives interview to The Medicine Maker.

OxSonics CEO, Jérôme Marzinski, gives interview to The Medicine Maker.

Oxford, UK – 2nd January 2023 – OxSonics CEO, Jérôme Marzinski, was interviewed by The Medicine Maker as part of their DISCOVERY & DEVELOPMENT series.

Please find the print version of the interview here:

– ENDS –


OxSonics Therapeutics
Jérôme Marzinski, Chief Executive Officer+44 (0)1865 784777  
Walbrook PR (media enquiries)Stephanie Cuthbert / Phillip Marriage+44 (0) 20 7933 8780 or
+44 (0)7796 794 663  

About OxSonics Therapeutics

OxSonics is a clinical-stage therapeutics company, transforming cancer treatment by harnessing its first-in-class, proprietary technology platform SonoTran® to enhance the delivery and improve the efficacy of oncology drugs. 

Current oncology drugs are restricted by their poor ability to penetrate solid tumors.

SonoTran® is being developed to provide a step-change in the therapeutic index of the drugs without the development costs or delays associated with drug reformulation. It combines Particles that are co-administered independently with an anti-cancer drug, and activated by a novel ultrasound device, creating a localised pumping effect that increases the delivery and penetration of the anti-cancer drug throughout the tumor. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumor cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing vizualisation on-screen and in real time.

SonoTran® is currently being evaluated in a phase I/IIa proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases.

The SonoTran® drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK. 

For more information please visit: